(Q44441338)

English

Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau).

scientific article published on 31 October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau). (English)

1 reference

Europe PubMed Central

3 December 2017

1 reference

based on heuristic

inferred from title

Maciej Kwiatkowski

9

object named as

Maciej Kwiatkowski

1 reference

Europe PubMed Central

3 December 2017

8

object named as

Franz Recker

1 reference

Europe PubMed Central

3 December 2017

author name string

Marco Randazzo

1

1 reference

Europe PubMed Central

3 December 2017

Josef Beatrice

2

1 reference

Europe PubMed Central

3 December 2017

Andreas Huber

3

1 reference

Europe PubMed Central

3 December 2017

Rainer Grobholz

4

1 reference

Europe PubMed Central

3 December 2017

Lukas Manka

5

1 reference

Europe PubMed Central

3 December 2017

Stephen F Wyler

6

1 reference

Europe PubMed Central

3 December 2017

Felix F Chun

7

1 reference

Europe PubMed Central

3 December 2017

publication date

31 October 2014

1 reference

Europe PubMed Central

3 December 2017

World Journal of Urology

1 reference

Europe PubMed Central

3 December 2017

33

1 reference

Europe PubMed Central

3 December 2017

8

1 reference

Europe PubMed Central

3 December 2017

1189-1196

1 reference

Europe PubMed Central

3 December 2017

https://scigraph.springernature.com/pub.10.1007/s00345-014-1426-y

0 references

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Type 2 diabetes and the risk of mortality among patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Metformin and other biguanides in oncology: advancing the research agenda

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

New perspective for an old antidiabetic drug: metformin as anticancer agent.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Association between metformin use and risk of prostate cancer and its grade

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Metformin use and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Prostate-cancer mortality at 11 years of follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Risk of cancer in a large cohort of U.S. veterans with diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Association of diabetes with prostate cancer risk in the multiethnic cohort

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values?

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

A review of the healthy worker effect in occupational epidemiology

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

"Predictability of body mass index for diabetes: affected by the presence of metabolic syndrome?"

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

PSA is Dead, Long Live PSA

1 reference

https://api.crossref.org/works/10.1007%2FS00345-014-1426-Y

21 January 2018

Association between metformin use and mortality in patients with prostate cancer: explained by confounding by indication?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25358675

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of type 2 diabetes on the outcome of localized renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25358675

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin and the incidence of prostate cancer in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25358675

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25358675

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25358675

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00345-014-1426-Y

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44441338&oldid=1769062500"